» Articles » PMID: 2968911

PET Measurement of D2 and S2 Receptor Binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in Baboon Brain

Overview
Journal Eur J Nucl Med
Specialty Nuclear Medicine
Date 1988 Jan 1
PMID 2968911
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The regional pharmacokinetic behavior in baboon brain of 18F-fluoroethyl- and 18F-fluoropropylspiperone (18FESP, 18FPSP) at specific activities greater than or equal to 1000 Ci/mmol was studied with PET. Four hours after injection of 5-10 mCi 18FESP, uptake in striatum was 0.048% +/- 0.005% of injected dose per cm3, which is almost the same as with 18F- and 11C-methylspiperone. While 18FPSP was taken up in much smaller amounts than 18FESP, striatum to cerebellum activity ratios were quite similar for both ligands (about 9 to 10 at 4 h p.i.). Because of its higher striatal uptake, 18FESP seems to be better suited for PET. Furthermore, relative binding to S2 receptors was much smaller for FESP: competing cold S2 antagonists (ritanserin, ketanserin) did not alter 18FESP binding to striatum, concurrently reducing uptake in frontal cortex by only 15%-20%. With coinjection of increasing amounts of cold FESP, saturation of 18FESP binding to striatum occurred at doses exceeding 10 micrograms per kg. Quantitative analysis of radiolabelled ligand in arterial plasma (decrease to 8% at 4 h p.i.) demonstrated identical metabolic turnover for both ligands. Direct use of binding fractions from the saturation curve resulted in overestimation of the receptor density in striatum. Using the 18FESP plasma concentration time curve and the dynamic uptake data, k3 of a three compartment model could be determined by non linear regression. However, dramatic changes of the dependence of k3 on the specifically bound ligand concentration were observed even at small loading doses of FESP. Estimation of Bmax yielded a D2 receptor density of only 6 pmol per cm3 in baboon striatum.

Citing Articles

Application of palladium-mediated (18)F-fluorination to PET radiotracer development: overcoming hurdles to translation.

Kamlet A, Neumann C, Lee E, Carlin S, Moseley C, Stephenson N PLoS One. 2013; 8(3):e59187.

PMID: 23554994 PMC: 3595243. DOI: 10.1371/journal.pone.0059187.


Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.

Antenor-Dorsey J, Markham J, Moerlein S, Videen T, Perlmutter J Nucl Med Biol. 2008; 35(3):335-41.

PMID: 18355689 PMC: 2390782. DOI: 10.1016/j.nucmedbio.2007.12.004.


Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates.

Antenor-Dorsey J, Laforest R, Moerlein S, Videen T, Perlmutter J Eur J Nucl Med Mol Imaging. 2007; 35(4):771-8.

PMID: 18071701 PMC: 3017464. DOI: 10.1007/s00259-007-0644-6.


Difference in response of D2 receptor binding between 11C-N-methylspiperone and 11C-raclopride against anesthetics in rhesus monkey brain.

Kobayashi K, Inoue O, Watanabe Y, Onoe H, Langstrom B J Neural Transm Gen Sect. 1995; 100(2):147-51.

PMID: 8962684 DOI: 10.1007/BF01271537.


Quantification of the whole-body distribution of PET radiopharmaceuticals, applied to 3-N-([18F]fluoroethyl)spiperone.

Herzog H, Coenen H, Kuwert T, Langen K, Feinendegen L Eur J Nucl Med. 1990; 16(2):77-83.

PMID: 2311622 DOI: 10.1007/BF01465913.


References
1.
Welch M, Chi D, Mathias C, Kilbourn M, Brodack J, Katzenellenbogen J . Biodistribution of N-alkyl and N-fluoroalkyl derivatives of spiroperidol; radiopharmaceuticals for PET studies of dopamine receptors. Int J Rad Appl Instrum B. 1986; 13(5):523-6. DOI: 10.1016/0883-2897(86)90132-7. View

2.
Olsen R, Reisine T, Yamamura H . Neurotransmitter receptors-biochemistry and alterations in nueropsychiatric disorders. Life Sci. 1980; 27(10):801-8. DOI: 10.1016/0024-3205(80)90073-9. View

3.
List S, Seeman P . Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions. Proc Natl Acad Sci U S A. 1981; 78(4):2620-4. PMC: 319401. DOI: 10.1073/pnas.78.4.2620. View

4.
Kiesewetter D, Eckelman W, Cohen R, Finn R, Larson S . Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens. Int J Rad Appl Instrum A. 1986; 37(12):1181-8. DOI: 10.1016/0883-2889(86)90003-1. View

5.
Arnett C, Shiue C, Wolf A, Fowler J, Logan J, Watanabe M . Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography. J Neurochem. 1985; 44(3):835-44. DOI: 10.1111/j.1471-4159.1985.tb12891.x. View